title: Peptide-Based Cancer Vaccine Strategies and Clinical Results.
abstract: Active cancer immunotherapy is an exciting and developing field in oncology research. Peptide vaccines, the use of isolated immunogenic tumor-associated antigen (TAA) epitopes to generate an anticancer immune response, are an attractive option as they are easily produced and administered with minimal toxicity. Multiple TAA-derived peptides have been identified and evaluated with various vaccine strategies currently in clinical testing. Research suggests that utilizing vaccines in patients with minimal-residual disease may be a more effective strategy compared to targeting patients with widely metastatic disease as it avoids the immune suppression and tolerance associated with higher volumes of more established disease. Clinical trials also suggest that vaccines may need to be tailored and administered to specific cancer subtypes to achieve maximum efficacy. Additionally, numerous immunomodulators now in research and development show potential synergy with peptide vaccines. Our group has focused on a simpler, single-peptide strategy largely from the HER2/neu protein. We will discuss our experience thus far as well as review other peptide vaccine strategies that have shown clinical efficacy.
authors.affiliation: Cancer Insight, LLC, 600 Navarro Street, Suite 500, San Antonio, TX, 78205, USA. ejschneble@gmail.com.
authors.forename: Erika
authors.initials: E
authors.lastname: Schneble
authors.affiliation: Cancer Insight, LLC, 600 Navarro Street, Suite 500, San Antonio, TX, 78205, USA.|Department of Surgical Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors.forename: G Travis
authors.initials: GT
authors.lastname: Clifton
authors.affiliation: Cancer Insight, LLC, 600 Navarro Street, Suite 500, San Antonio, TX, 78205, USA.|San Antonio Military Medical Center, 3551 Roger Brooke Drive, San Antonio, TX, 78234, USA.
authors.forename: Diane F
authors.initials: DF
authors.lastname: Hale
authors.affiliation: Cancer Insight, LLC, 600 Navarro Street, Suite 500, San Antonio, TX, 78205, USA.
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D022223:Vaccines, Subunit
keywords: Cancer vaccine; Immunotherapy; Peptide; Tumor-associated antigen